SCHEMBL2659261

SCHEMBL2659261

CC1(C)COB(c2ccc(Cl)c(-c3cccnc3)c2)OC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 5/20 0.39
CYP2A6 P11509 3/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NPY5R Q15761 2/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MTOR P42345 1/20 0.36
ROS1 P08922 1/20 0.35
ABL1 P00519 1/20 0.35
CYP11B1 P15538 4/20 0.35
CYP17A1 P05093 3/20 0.35
CYP3A4 P08684 2/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
KDR P35968 1/20 0.35
SNCA P37840 1/20 0.35
CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6217350 0.86 CYP2A6 (0.40) CYP11B2CYP2A6NPC1RAB9ANPY5R
SCHEMBL6220588 0.83 CYP11B1 (0.45) CYP11B2NPC1RAB9ANPY5RSMN1; SMN2
SCHEMBL2658270 0.80 MEN1 (0.44) CYP11B2CYP2A6CYP11B1CYP17A1CYP3A4
SCHEMBL13188238 0.80 CYP2A6 (0.46) CYP11B2CYP2A6CYP11B1CYP3A4MKNK1
SCHEMBL4078174 0.75 MAPT (0.36) CYP2A6NPC1RAB9ATP53SMN1; SMN2
SCHEMBL2655829 0.74 DYRK1A (0.54) CYP2A6CYP3A4MKNK1MKNK2SNCA
SCHEMBL2650049 0.73 CYP11B1 (0.40) CYP11B2CYP2A6NPY5RABL1CYP11B1
SCHEMBL18548331 0.73 SNCA (0.35) SNCA
SCHEMBL6219095 0.72 SNCA (0.34) SNCA
SCHEMBL2659991 0.72 NPC1 (0.38) CYP11B2NPC1RAB9ANPY5RSNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343788-B1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-11-23 EP disclosed
US-6936608-B2 Imidazo-triazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LTD. 2005-08-30 US disclosed
EP-1381606-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-07-20 EP disclosed
US-6900215-B2 For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders MERCK SHARP & DOHME LTD. (GB) 2005-05-31 US disclosed
US-20040023964-A1 Imidazo-triazine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2004-02-05 US disclosed
EP-1343788-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2003-09-17 EP disclosed
US-20020193385-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors MERCK SHARP & DOHME (UK) LIMITED (GB) 2002-12-19 US disclosed
WO-2002038568-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193385-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors GABRA3, GABRA1, GABRA2 CYP11B2 952/4885CYP2A6 552/4885NPC1 2277/4885
US-20040023964-A1 Imidazo-triazine derivatives as ligands for gaba receptors GABRA2, GABRA5, GABRA1 CYP11B2 374/4885CYP2A6 897/4885NPC1 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.